Caroline J. Rieser

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Amer H. Zureikat · 11 shared papers, 2018–2025 · strength 1.44
   • Paper Pancreatic Cancer Multidisciplinary Clinic is Associated with Improved Treatment and Elimination of Socioeconomic Dispa… DOI 10.1245/s10434-023-14609-7↗
   • Paper Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic… DOI 10.1245/s10434-025-16916-7↗
   • Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
2. Alessandro Paniccia · 6 shared papers, 2021–2025 · strength 0.92
   • Paper Pancreatic Cancer Multidisciplinary Clinic is Associated with Improved Treatment and Elimination of Socioeconomic Dispa… DOI 10.1245/s10434-023-14609-7↗
   • Paper Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic… DOI 10.1245/s10434-025-16916-7↗
   • Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
3. Herbert J. Zeh · 7 shared papers, 2018–2025 · strength 0.81
   • Paper Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic… DOI 10.1245/s10434-025-16916-7↗
   • Paper Correction to: Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Ad… DOI 10.1245/s10434-020-08249-4↗
   • Paper Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected P… DOI 10.1245/s10434-019-08094-0↗
4. Melissa Ellen Hogg · 6 shared papers, 2018–2025 · strength 0.70
   • Paper Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic… DOI 10.1245/s10434-025-16916-7↗
   • Paper Correction to: Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Ad… DOI 10.1245/s10434-020-08249-4↗
   • Paper CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreat… DOI 10.1245/s10434-020-08468-9↗
5. Nathan Bahary · 6 shared papers, 2018–2023 · strength 0.66
   • Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
   • Paper Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adeno… DOI 10.1002/jso.26510↗
   • Paper Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected P… DOI 10.1245/s10434-019-08094-0↗
6. Amr I. Al Abbas · 5 shared papers, 2018–2020 · strength 0.52
   • Paper Correction to: Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Ad… DOI 10.1245/s10434-020-08249-4↗
   • Paper Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected P… DOI 10.1245/s10434-019-08094-0↗
   • Paper CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreat… DOI 10.1245/s10434-020-08468-9↗
7. Richard S. Hoehn · 3 shared papers, 2021–2024 · strength 0.46
   • Paper Pancreatic Cancer Multidisciplinary Clinic is Associated with Improved Treatment and Elimination of Socioeconomic Dispa… DOI 10.1245/s10434-023-14609-7↗
   • Paper Medicaid expansion and the management of pancreatic cancer. DOI 10.1002/jso.26515↗
   • Paper A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. DOI 10.1245/s10434-021-09594-8↗
8. Brian A. Boone · 3 shared papers, 2019–2025 · strength 0.40
   • Paper Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic… DOI 10.1245/s10434-025-16916-7↗
   • Paper Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected P… DOI 10.1245/s10434-019-08094-0↗
   • Paper Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy … DOI 10.1245/s10434-018-07148-z↗
9. Aatur Dilip Singhi · 3 shared papers, 2020–2023 · strength 0.35
   • Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
   • Paper CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreat… DOI 10.1245/s10434-020-08468-9↗
   • Paper A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. DOI 10.1245/s10434-021-09594-8↗
10. Asmita Chopra · 2 shared papers, 2021–2025 · strength 0.31
    • Paper Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic… DOI 10.1245/s10434-025-16916-7↗
    • Paper Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adeno… DOI 10.1002/jso.26510↗
11. Ahmad B. Hamad · 3 shared papers, 2018–2020 · strength 0.30
    • Paper Correction to: Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Ad… DOI 10.1245/s10434-020-08249-4↗
    • Paper Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy … DOI 10.1245/s10434-018-07148-z↗
    • Paper CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis … DOI 10.1245/s10434-018-6521-7↗
12. Samer S. AlMasri · 2 shared papers, 2021–2023 · strength 0.26
    • Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
    • Paper Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adeno… DOI 10.1002/jso.26510↗
13. Ibrahim Nassour · 2 shared papers, 2021 · strength 0.24
    • Paper Medicaid expansion and the management of pancreatic cancer. DOI 10.1002/jso.26515↗
    • Paper Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adeno… DOI 10.1002/jso.26510↗
14. David L. Bartlett · 2 shared papers, 2021 · strength 0.21
    • Paper Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adeno… DOI 10.1002/jso.26510↗
    • Paper A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. DOI 10.1245/s10434-021-09594-8↗
15. Sarah B. Hays · 1 shared paper, 2025 · strength 0.19
    • Paper Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic… DOI 10.1245/s10434-025-16916-7↗
16. Patricio Marcelo Polanco · 1 shared paper, 2025 · strength 0.19
    • Paper Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic… DOI 10.1245/s10434-025-16916-7↗
17. Amudhan Kannan · 1 shared paper, 2025 · strength 0.19
    • Paper Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic… DOI 10.1245/s10434-025-16916-7↗
18. Imad Radi · 1 shared paper, 2025 · strength 0.19
    • Paper Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic… DOI 10.1245/s10434-025-16916-7↗
19. Emile Farah · 1 shared paper, 2025 · strength 0.19
    • Paper Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic… DOI 10.1245/s10434-025-16916-7↗
20. Mark S. Talamonti · 1 shared paper, 2025 · strength 0.19
    • Paper Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic… DOI 10.1245/s10434-025-16916-7↗
21. Hussein H. Khachfe · 1 shared paper, 2023 · strength 0.15
    • Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
22. Hao Liu · 1 shared paper, 2023 · strength 0.15
    • Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
23. Samer T. Tohme · 1 shared paper, 2021 · strength 0.13
    • Paper Medicaid expansion and the management of pancreatic cancer. DOI 10.1002/jso.26515↗
24. Christof Kaltenmeier · 1 shared paper, 2021 · strength 0.13
    • Paper Medicaid expansion and the management of pancreatic cancer. DOI 10.1002/jso.26515↗
25. Jae Pil Jung · 1 shared paper, 2020 · strength 0.12
    • Paper Correction to: Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Ad… DOI 10.1245/s10434-020-08249-4↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.